Roche Holding said its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, bolstering the Swiss drugmaker’s defense against a wave of cut-price competition to its top-selling medicines.
from WSJ.com: US Business http://ift.tt/2AgqhF9
via IFTTT
No comments:
Post a Comment